For the ones who actually read the studies.

Tesamorelin: The GHRH Analogue With Real Trial Data Behind It

Tesamorelin is an FDA-approved GHRH analogue with strong trial evidence for reducing visceral fat in HIV-associated lipodystrophy, but off-label use rests on weaker ground.

Evidence gap · The strong evidence comes almost entirely from HIV-associated lipodystrophy; use for general fat loss, non-HIV fatty liver, or anti-ageing is extrapolation with no trial support. Long-term cardiovascular benefit is not established, and the effect reverses after stopping.

GHK-Cu (Copper Peptide): What the Evidence Actually Shows

A clear-eyed look at GHK-Cu: strong lab and animal mechanism data, thin human evidence, and why much of the glowing skincare literature comes with a conflict of interest.

BPC-157: What the Evidence Actually Shows

A clear-eyed look at BPC-157: a peptide with promising rodent healing data, almost no human evidence, and serious regulatory and sourcing caveats.

Evidence gap · Almost all healing evidence comes from rodent studies dominated by a single research group, with no completed human efficacy or safety trials and only one small, uncontrolled human case series. The popular recovery claims remain promising but essentially unproven in people.